DUBLIN, Calif.--(BUSINESS WIRE)--SuperGen, Inc. (NASDAQ: SUPG) today reported financial results for the first quarter ended March 31, 2009. “SuperGen made significant progress with respect to the discovery and development of novel drugs during the first quarter of 2009,” said James S.J. Manuso, Ph.D., President and Chief Executive Officer. “Our DNA damage repair inhibitor, MP-470, has now been in more than 100 patients, the Company’s first-in-class PIM kinase inhibitor, SGI-1776, entered Phase I clinical trials, and the discovery of a series of drug candidates for the inhibition of the Etk/Bmx protein was recently announced at the 100th Annual Meeting of the American Association for Cancer Research. We continue to maintain a strong financial position, with sufficient operating cash to fund the development initiatives planned for 2009, and well into the following year.”
